Sign In/ Sign Up
Increased use of stereotactic body radiation therapy (SBRT) to treat patients with stage I non-small cell lung cancer (NSCLC) doubles survival rates: ASTRO Study
Oct 2, 2016
A new analysis of records in the Veteran’s Affairs Central Cancer Registry demonstrates a clear positive impact of the increased use of stereotactic body radiation therapy (SBRT) to treat patients with stage I non-small cell lung cancer (NSCLC) in recent years, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO). Escalated adoption of this advanced form of radiation therapy (RT) from 2001 to 2010 was associated with substantial increases in overall survival (OS) rates and lung cancer specific survival (LCSS) rates.